中文摘要：

目的观察肾透明细胞癌（ccRCC）与正常肾组织中ALS2CL基凶的表达及差异，并探讨其意义。方法采用实时定量聚合酶链反应（Real—timePCR）、免疫组织化学（IPH）及Westernblot检测26例配对癌组织／癌旁正常肾组织标本及2株ccRCC来源细胞（786／0、SN12-PM6）中ALS2CL基凶mRNA和蛋白的表达。结果与正常对照组比较，ALS2CL基凶mRNA在65．38％（17／26）的ccRCC组织中表达显著下调，在786／0、SN12-PM6中表达亦显著下调；IPH结果示73．08％（19／26）ccRCC组织ALS2CL蛋白呈阴性或弱阳性表达；Westernblot结果示53．58％（14／26）ccRCC组织ALS2CL蛋白表达下调，2株细胞ALS2CL蛋白表达亦下调，与各自对照组比较，其表达差异均有统计学意义（P〈0．05）。结论ALS2CL基因表达缺失或下调可能与肾透明细胞癌发生密切相关。

英文摘要：

Objective To study the differential expression of ALS2CL in clear cell renal cell carcinoma （ecRCC） and normal kidney tissue and the implication. Methods Real-time quantitative polymerase chain reaction （Real-time PCR）, immunohistochemistry （IPH） and Western blotting were applied to examine the expression status of ALS2CL in 26 ccRCC tumor and adjacent normal kidney tissue samples as well as two kinds of ccRCC-derived cell lines （786/0, SN12-PM6）. Results As compared with normal control group, the two ccRCC-derived cell lines （786/O, SN12-PM6） and 65.38% （17/26） of ccRCC alls showed an obvious down-regulated expression of ALS2CL mRNA. Under the examination of ALS2CL protein by IPH, 73.08% （19/26） of ccRCC specimens were negative or weakly positive, Western blotting also showed a highly down-regulated rate-53.85% （14/26） in ccRCC samples, and the low expression of ALS2CL was also found in 786/0 and SN12-PM6 cells. All of them showed statistically significant differ- ence between ccRCC group and corresponding normal control group （ P 〈 0. 05 ）. Conclusion The absence or downregulated expression of ALS2CL may be closely related to the occurrence of ccRCC.